Cancers & treatments·Regimen libraryCurative

CHOP

Checked 2026-09-09

Peripheral T-cell lymphomas first line (often with etoposide as CHOEP, or brentuximab replacing vincristine for CD30-positive disease); the historical backbone of R-CHOP in B-cell lymphoma

One cycle

every 21 days × 6 · about 18 weeks in total

21-day cycle × 6 (about 18 weeks)IntravenousOral Daily oral course

Components

Drug	Dose	Route	Days
Cyclophosphamide Alkylating agent (oxazaphosphorine prodrug)	750 mg/m²	IV	D1
Doxorubicin Cytotoxic chemotherapy (anthracycline)	50 mg/m²	IV	D1
Vincristine Vinca alkaloid (microtubule inhibitor)	1.4 mg/m² (maximum 2 mg)	IV	D1
Prednisone Glucocorticoid	100 mg once daily	Oral	D1-5

Cycles

21-day cycle

Emetogenicity

High (>90%)

G-CSF

Consider (10-20% FN risk)

Notes

In B-cell lymphoma rituximab is added (R-CHOP); CHOP alone remains the comparator in T-cell lymphoma trials.
Check LVEF before doxorubicin; G-CSF for patients over 65 or with comorbidity.

Used in

Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)Diffuse large B-cell lymphoma

Products

CyclophosphamideDoxorubicinVincristinePrednisone

Source

Fisher (SWOG 8516), NEJM 1993: CHOP equal to third-generation regimens

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.